Fibrodysplasia Ossificans Progressiva (FOP) Completed Phase 2 Trials for Palovarotene (DB05467)

Also known as: FOP / Fibrodysplasia Ossificans Progressiva / Myositis ossificans progressiva, unspecified site / Myositis ossificans progressiva / Progressive myositis ossificans / Progressive myositis ossificans (disorder)

IndicationStatusPhase
DBCOND0086420 (Fibrodysplasia Ossificans Progressiva (FOP))Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02279095An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)Treatment
NCT02979769An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in People With Fibrodysplasia Ossificans Progressiva (FOP) in FranceTreatment
NCT02190747An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP SubjectsTreatment